The open heart surgery were successfully performed in 820 patients undergoing cardiopulmonary bypass in our hospital during last sixteen years. Of them 30 cases occurred accidental complications. In this article, the major causes of the complications were analysed and diseussed emphatically. And the corresponding measures in prevention and treatment were also put forword.

Objective To investigate the role of FHIT protein and cPKC? in invasion and metastasis in non-small cell lung cancer(NSCLC).Methods The expression of FHIT protein and cPKC? in 41 specimens of NSCLC and 11 cases benign lung tissues were examined by immunohistochemical technique.Results The positive rate of FHIT protein and cPKC? in NSCLC tissues were 48.8% and 53.7% respectively.The positive rate of FHIT protein and cPKC? in benign lung tissues were 90.9% and 18.2% respectively.They were significantly different(P

Objectire To identify specific biomarkers that could improve early diagnsis of lung adenuearcinoma using matrix-assisted laser desorptian/ionization (MALDI) technology. Methods Serum samples were isolated from 17 patients with stage I lung adenuearcinoma and 17 age- and sex-matched healthy controls, and the serum proteomic profiles were obtained by matrix-assistcd laser desorption ionization time of flight (MALDI-TOF) mass spectrometry. Results Compared with healthy control group, two highly expressed potential biomarkers were identified with the relative molecular weights of 6 631.64 Da and 4 964. 21 Da. The two best novel protein peaks were automatically chosen for the system training and the development of the constructed model. The constructed model was then used to test an independent set of masked serum samples from 15 lung adenocarcinoma patients and 22 healthy individuals. The analysis yielded a sensitivity of 93.3 %, and a specificity of 95.5 %. Conclusion These results suggest that MALDI-TOF-MS ProteinChip technology is a quick, convenient, and high-output analyzing method that is capable of selecting several relatively potential biomarkers from the serum of lung adenocarcinoma patients and may have a clinical value in the future, and will provide clues to identifying new serologic btomarkers of lung adenocarcinoma.

Objective To make a comparative analysis of conventional smear and liquid-based cytology method to diagnose lung cancer in sensitivity and false-negative,and evaluate the application value of liquid-based cytology in sputum samples.Methods We collected 287 sputum samples through clinical contrast conventional smear with liquid-based cytology method.The diagnosis was made by the same pathology panel in double blind way.We compared the two methods to diagnose lung cancer in sensitivity and false-negative.Results Liquid-based cytology method detected 62 cases of lung cancer,and conventional smear detected 49 cases of lung cancer,with the sensitivity rate being 21.6% and 17.1%,respectively.Combination of the two methods made the sensitivity rate 24.0%.The false-negative rate was 38.6% for liquid-based cytology method and 48.5% for conventional smear which did not differ significantly.By combining the two methods,the false-negative rate was 24.0%.There was no significant difference between liquid-based cytology method and conventional smear,and between liquid-based cytology method and the two-method combination in sensitivity and false-negative.But there was a significant difference between the two-method combination and conventional smear.Conclusion Through sputum sample detection of lung cancer cell,liquid-based cytology method is better than conventional smear,the former having obvious superiority;combining the two methods can detect more lung cancers.Therefore,it is a superior screening test in detecting lung cancer and worthy of clinical popularization.

Objective:To investigate the effects of hemophagocytic syndrome also known as hemophagocytic lymphohistiocytosis (HLH) on the clinical features and therapeutic efficacy of patients with Epstein-Barr virus-positive T-cell lymphoma (EBV-TCL).Methods:The clinical data of patients with EBV-TCL diagnosed by pathological examination in the First Affiliated Hospital of Guangzhou Medical University from November 2015 to August 2020 were retrospectively analyzed. According to whether they were accompanied with HLH at the time of onset, patients were divided into HLH group (10 cases) and non-HLH group (13 cases), and the clinical features and prognosis of the two groups were compared. The curative effects of different treatment methods and patients with different plasma EBV-DNA titers were compared.Results:Among 23 patients, 3 cases (13.0%) were in Ann Arbor stage Ⅰ-Ⅱ, 20 cases (87.0%) were in stage Ⅲ-Ⅳ; the International Prognostic Index (IPI) score was 1 point in 3 cases (13.0%), 2 points in 4 cases (17.4%), 3 points in 8 cases (34.8%), 4 points in 8 cases (34.8%). In the HLH group, there were 2 cases of aggressive NK-cell leukemia and 3 cases of childhood systemic EBV-TCL. There were no cases of above two pathological types in the non-HLH group. In the HLH group, the proportions of patients with fever, bone marrow invasion, IPI score > 2 points, and EBV-DNA > 10 4 copies/ml were higher than those in the non-HLH group (all P < 0.05). The objective response rate (complete remission plus partial remission) of all patients after chemotherapy was 47.8% (11/23); there were 3 cases undergoing hematopoietic stem cell transplantation in both the HLH group and the non-HLH group, and all achieved objective remission. The objective remission of 7 patients and 10 patients who did not undergo hematopoietic stem cell transplantation in the HLH group and non-HLH group after lymphoma chemotherapy had 0 case and 5 cases, respectively, and the difference was statistically significant ( P = 0.044). In the chemotherapy alone group, 5 of 17 patients had objective remission, 6 patients in the chemotherapy plus transplantation group had objective remission, and the difference was statistically significant ( P = 0.039). Among 16 patients whose plasma EBV-DNA titers turned negative, 11 patients had objective remission, and 7 patients whose plasma EBV-DNA titers were continuously positive had no objective remission, and the difference was statistically significant ( P = 0.001). The 1-year overall survival rate of all patients was 69.3%, and the 2-year overall survival rate was 52.0%. In the HLH group, the 1-year and 2-year overall survival rates of 7 patients receiving chemotherapy alone and 3 patients receiving chemotherapy plus transplantation were 42.9% and 66.7%, respectively. In the non-HLH group, the 1-year overall survival rates of 10 patients receiving chemotherapy alone and 3 patients receiving chemotherapy plus transplantation were 80.0% and 100.0%, respectively; the 2-year overall survival rates were 26.7% and 100.0%,respectively. The overall survival of patients receiving chemotherapy plus transplantation was better than that of those receiving chemotherapy alone in both the HLH group and the non-HLH group, and differences were statistically significant (all P < 0.05). Conclusions:The general clinical stage of patients with EBV-TCL is later, and the prognosis of EBV-TCL patients with HLH is worse. The therapeutic efficacy may be related to plasma EBV-DNA titers. Hematopoietic stem cell transplantation can improve the remission rate.